Dispersion of serum 1,5 anhydroglucitol values in patients with type 2 diabetes at goal of HbA1c

Chávez, Jaime; Sánchez, Elsa Rosa Neira; Ferrara, Luciano Francesco Poletti

doi:10.1016/j.diabres.2023.110668

Cited by 4 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When CKD progresses to stages 4–5, 1,5-AG loses its role in reflecting glycemic changes due to a severe decrease in eGFR [ 10 ]. Changes or fluctuations in blood glucose, above average blood glucose levels, may damage the vascular system, which may lead to the advancement of kidney disease [ 19 ]. Recent studies described that sodium-glucose cotransporter 4 as a potential transporter for 1,5-AG.…”

Section: Discussionmentioning

confidence: 99%

The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients

Wang,

Yang

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients

Wang,

Yang

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Gormsen et al [ 23 ] reported that 1,5-AG was associated with the glucose-lowering effect of metformin. Similarly, Villena Chávez et al recently reported, in a study involving one hundred outpatients with T2D, that patients with HbA1c < 7% had significantly higher 1,5-AG than those with HbA1c ≥ 7% [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Pharmacometabolomic Approach to Investigate the Response to Metformin in Patients with Type 2 Diabetes: A Cross-Sectional Study

Naja,

Anwardeen,

Al-Hariri

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Metformin constitutes the foundation therapy in type 2 diabetes (T2D). Despite its multiple beneficial effects and widespread use, there is considerable inter-individual variability in response to metformin. Our objective is to identify metabolic signatures associated with poor and good responses to metformin, which may improve our ability to predict outcomes for metformin treatment. In this cross-sectional study, clinical and metabolic data for 119 patients with type 2 diabetes taking metformin were collected from the Qatar Biobank. Patients were empirically dichotomized according to their HbA1C levels into good and poor responders. Differences in the level of metabolites between these two groups were compared using orthogonal partial least square discriminate analysis (OPLS-DA) and linear models. Good responders showed increased levels of sphingomyelins, acylcholines, and glutathione metabolites. On the other hand, poor responders showed increased levels of metabolites resulting from glucose metabolism and gut microbiota metabolites. The results of this study have the potential to increase our knowledge of patient response variability to metformin and carry significant implications for enabling personalized medicine.

show abstract

“…Postprandial hyperglycemia and blood glucose fluctuations contribute to the development of cardiovascular disease, while 1,5-AG is a reliable indicator of monitoring postprandial hyperglycemia and reflecting short-term blood glucose fluctuations, which can be used to reduce the occurrence of cardiovascular disease in diabetic patients by monitoring the 1,5-AG levels ( 78 , 79 ). A prospective observational study of 1,5-AG and cardiovascular diseases found that low levels of 1,5-AG (<6.0 µg/mL) were closely related to cardiovascular disease ( 80 ), and the lower levels of 1,5-AG indicated the higher mortality of cardiovascular events ( 81 ).…”

Section: Progress Of Clinical Research On 15-ag For Diabetes Complica...mentioning

confidence: 99%

The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications

Xu,

Pan,

Chen

2024

Front. Endocrinol.

View full text Add to dashboard Cite

1,5-Anhydroglucitol (1,5-AG) is sensitive to short-term glucose fluctuations and postprandial hyperglycemia, which has great potential in the clinical application of diabetes as a nontraditional blood glucose monitoring indicator. A large number of studies have found that 1,5-AG can be used to screen for diabetes, manage diabetes, and predict the perils of diabetes complications (diabetic nephropathy, diabetic cardiovascular disease, diabetic retinopathy, diabetic pregnancy complications, diabetic peripheral neuropathy, etc.). Additionally, 1,5-AG and β cells are also associated with each other. As a noninvasive blood glucose monitoring indicator, salivary 1,5-AG has much more benefit for clinical application; however, it cannot be ignored that its detection methods are not perfect. Thus, a considerable stack of research is still needed to establish an accurate and simple enzyme assay for the detection of salivary 1,5-AG. More clinical studies will also be required in the future to confirm the normal reference range of 1,5-AG and its role in diabetes complications to further enhance the blood glucose monitoring system for diabetes.

show abstract

Dispersion of serum 1,5 anhydroglucitol values in patients with type 2 diabetes at goal of HbA1c

Cited by 4 publications

References 38 publications

The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients

The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients

Pharmacometabolomic Approach to Investigate the Response to Metformin in Patients with Type 2 Diabetes: A Cross-Sectional Study

The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications

Contact Info

Product

Resources

About